person · Reporting owner

DILLY STEPHEN GEORGE

Disclosed activity across 4 companies

Tapewire entity: 36739
SEC CIK: 0001389147

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aimmune Therapeutics, Inc.AIMT · Entity 145931	Director · President and CEO	June 11, 2018	June 13, 2018
CODEXIS, INC.CDXS · Entity 6428	Director	June 17, 2026	June 18, 2026
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	May 18, 2020	June 03, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aimmune Therapeutics, Inc.

Report date June 11, 2018 · Filed June 13, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	315,308	Ending reported balance After 2018-06-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-06-11 · Exercise / conversion · Acquired 29,457 · Balance 344,765 Row 2 · 2018-06-11 · Sale · Disposed 29,457 · Balance 315,308 F1: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F2: The transaction was executed in multiple trades in prices ranging from $30.51 to $31.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2025-05-18	Direct	295,942	Reported balance After 2018-06-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-06-11 · Exercise / conversion · Disposed 29,457 · Balance 295,942 F8: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy GRAT 2	12,009	Reported balance Holding disclosure · report date 2018-06-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 12,009 F3: These shares are held by Stephen G. Dilly, Trustee, The Stephen G. Dilly 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the Second Dilly Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Wife's GRAT 2	12,009	Reported balance Holding disclosure · report date 2018-06-11 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 12,009 F4: These shares are held by Edwina Lynette Mullens, Trustee, The Edwina Lynette Mullens 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the Second Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the Second Mullens Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Family Trust	25,532	Reported balance Holding disclosure · report date 2018-06-11 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 25,532 F5: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Dilly Family Trust dated October 9, 2002 (the "Family Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Family Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Child's Trust 1	41,075	Reported balance Holding disclosure · report date 2018-06-11 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 41,075 F6: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Frederick S W Dilly 2015 Irrevocable Trust dated June 23, 2015 (the "Frederick S W Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Frederick S W Dilly Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Child's Trust 2	41,075	Reported balance Holding disclosure · report date 2018-06-11 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 41,075 F7: These shares are held by Edwina Lynette Mullens and Stephen G. Dilly as Trustees of The Harriet F.L. Dilly 2015 Revocable Trust dated June 23, 2015 (the "Harriet F.L. Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Harriet F.L. Dilly Trust.

Filing footnotes · ownership attribution and instrument terms

F1: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

F2: The transaction was executed in multiple trades in prices ranging from $30.51 to $31.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F3: These shares are held by Stephen G. Dilly, Trustee, The Stephen G. Dilly 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the Second Dilly Trust.

F4: These shares are held by Edwina Lynette Mullens, Trustee, The Edwina Lynette Mullens 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the Second Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the Second Mullens Trust.

F5: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Dilly Family Trust dated October 9, 2002 (the "Family Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Family Trust.

F6: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Frederick S W Dilly 2015 Irrevocable Trust dated June 23, 2015 (the "Frederick S W Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Frederick S W Dilly Trust.

F7: These shares are held by Edwina Lynette Mullens and Stephen G. Dilly as Trustees of The Harriet F.L. Dilly 2015 Revocable Trust dated June 23, 2015 (the "Harriet F.L. Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Harriet F.L. Dilly Trust.

F8: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

CODEXIS, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17	Direct	66,350	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350 F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

SANGAMO THERAPEUTICS, INC

Report date May 18, 2020 · Filed June 03, 2020 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,000	Reported balance After 2020-05-18 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2020-05-18 · Grant · Acquired 10,000 · Balance 15,000 F1: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.46 · Expires 2030-05-17	Direct	20,000	Reported balance After 2020-05-18 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2020-05-18 · Grant · Acquired 20,000 · Balance 20,000 F3: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

F3: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sierra Oncology, Inc.

Report date July 01, 2022 · Filed July 01, 2022

Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-07-01 transaction · row 1 1 source row Row 1 · 2022-07-01 · Disposition to issuer · Disposed 5,000 · Balance 0
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.03 · Expires 2030-06-01	Direct	Reported balance After 2022-07-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-07-01 · Disposition to issuer · Disposed 520,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12	Direct	Reported balance After 2022-07-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-07-01 · Disposition to issuer · Disposed 260,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15	Direct	Reported balance After 2022-07-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-07-01 · Disposition to issuer · Disposed 92,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14	Direct	Reported balance After 2022-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-07-01 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.

F3: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.

F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.

F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2026 Filed Jun 18, 2026 20:06 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantStock Option (Right to Buy) · Derivative	66,350	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001610717-26-000240 · form4.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,350 Underlying: Common Stock · 66,350 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document
November 11, 2025 Filed Nov 12, 2025 21:31 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	50,000	$1.85	$92,365.00	Disclosure SEC source: 0001610717-25-000374 · form4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,053 F1 · price: This transaction was executed in multiple trades in prices ranging from $1.7550 to $1.90, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 2,000 shares acquired under the issuer's Employee Stock Purchase Plan on May 10, 2025. F3 · balance_after: Includes 2,000 shares acquired under the issuer's Employee Stock Purchase Plan on November 10, 2025. Read SEC document
February 05, 2025 Filed Feb 8, 2025 01:15 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantStock Option (Right to Buy) · Derivative	532,500	$0.00 Strike: $4.37	$0.00	Disclosure SEC source: 0000905148-25-000438 · form4.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,500 Underlying: Common Stock · 532,500 shares Expires 2035-02-05 F3 · derivative.exercise_date: This option vests and becomes exercisable with respect to 25% of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/48th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document
February 05, 2025 Filed Feb 8, 2025 01:15 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	88,750	$0.00	$0.00	Disclosure SEC source: 0000905148-25-000438 · form4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,053 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. F2 · balance_after: Includes 2,000 shares acquired under the issuer's Employee Stock Purchase Plan on May 10, 2024. Read SEC document
January 01, 2024 Filed Jan 3, 2024 02:23 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantStock Option (Right to Buy) · Derivative	860,500	$0.00 Strike: $3.05	$0.00	Disclosure SEC source: 0000905148-24-000029 · form4.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 860,500 Underlying: Common Stock · 860,500 shares Expires 2034-01-01 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 1/3rd of the shares subject thereto on the first anniversary of the grant date, and with respect to 1/36th of the original number of shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document
January 01, 2024 Filed Jan 3, 2024 02:23 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	143,425	$0.00	$0.00	Disclosure SEC source: 0000905148-24-000029 · form4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 582,303 F1 · shares: These restricted stock units vest as to 1/3rd of the shares on each annual anniversary of the grant date, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document
September 08, 2023 Filed Sep 12, 2023 20:06 UTC	CODEXIS, INC. CDXS · Entity 6428	PurchaseCommon Stock	58,479	$1.73	$100,952.30	Disclosure SEC source: 0000905148-23-000900 · form4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,878 F1 · price: This transaction was executed in multiple trades in prices ranging from $1.71 to $1.73, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document
March 08, 2023 Filed Mar 10, 2023 02:15 UTC	CODEXIS, INC. CDXS · Entity 6428	SaleCommon Stock	26,987	$4.56	$122,931.18	Disclosure SEC source: 0001567619-23-004772 · doc1.xml · nonDerivative · entry 3 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,399 F2 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSUs of the Issuer. F3 · price: Reflects the weighted average of all shares sold to cover taxes upon vesting of PSUs on March 8, 2023 for certain employees of the Issuer. Read SEC document
March 07, 2023 Filed Mar 10, 2023 02:15 UTC	CODEXIS, INC. CDXS · Entity 6428	SaleCommon Stock	28,088	$4.60	$129,280.64	Disclosure SEC source: 0001567619-23-004772 · doc1.xml · nonDerivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,386 F2 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSUs of the Issuer. F3 · price: Reflects the weighted average of all shares sold to cover taxes upon vesting of PSUs on March 8, 2023 for certain employees of the Issuer. Read SEC document
February 21, 2023 Filed Feb 22, 2023 01:26 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantStock Option (Right to Buy) · Derivative	337,500	$0.00 Strike: $5.44	$0.00	Disclosure SEC source: 0001567619-23-003441 · doc1.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,500 Underlying: Common Stock · 337,500 shares Expires 2033-02-21 F2 · derivative.exercise_date: Option vests and becomes exercisable with respect to 25% of the shares subject thereto on February 21, 2024, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on February 21, 2027, in each case, subject to continued service through the applicable vesting date. Read SEC document
February 21, 2023 Filed Feb 22, 2023 01:26 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	112,500	$0.00	$0.00	Disclosure SEC source: 0001567619-23-003441 · doc1.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,474 F1 · shares: Restricted Stock Units ("RSUs") vest 1/3 annually from February 21, 2023 such that the RSUs will be fully vested on February 21, 2026. Each RSU represents a contingent right to receive one share of Codexis common stock. Read SEC document
February 08, 2023 Filed Mar 10, 2023 02:15 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	289,000	$0.00	$0.00	Disclosure SEC source: 0001567619-23-004772 · doc1.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,474 F1 · shares: Represents restricted stock awards ("PSUs") initially granted on November 8, 2022 that were subject a performance-based vesting condition. The vesting condition was determined to be 85% satisfied on February 8, 2023. The PSUs will vest fully on March 5, 2024, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document
August 01, 2022 Filed Aug 3, 2022 22:25 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $6.73	$0.00	Disclosure SEC source: 0001567619-22-014899 · doc1.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-08-01 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject thereto on August 1, 2023, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on August 1, 2026. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:35 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	165,000	$0.00 Strike: $31.54	$0.00	Disclosure SEC source: 0001209191-22-040252 · doc4.xml · derivative · entry 5 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2032-03-14 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:35 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	92,000	$0.00 Strike: $16.73	$0.00	Disclosure SEC source: 0001209191-22-040252 · doc4.xml · derivative · entry 4 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,000 shares Expires 2031-03-15 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4 · derivative.exercise_date: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:35 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	260,000	$0.00 Strike: $12.15	$0.00	Disclosure SEC source: 0001209191-22-040252 · doc4.xml · derivative · entry 3 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 260,000 shares Expires 2030-08-12 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3 · derivative.exercise_date: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:35 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	520,000	$0.00 Strike: $14.03	$0.00	Disclosure SEC source: 0001209191-22-040252 · doc4.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 520,000 shares Expires 2030-06-01 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1 · derivative.exercise_date: The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:35 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerCommon Stock	5,000	$55.00	$275,000.00	Disclosure SEC source: 0001209191-22-040252 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
June 17, 2022 Filed Jun 17, 2022 16:10 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	65,000	$0.00 Strike: $12.15	$0.00	Disclosure SEC source: 0001209191-22-037833 · doc4.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 65,000 shares. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:14 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	11,273	$0.00	$0.00	Disclosure SEC source: 0001567619-22-012978 · doc1.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,974 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document
March 14, 2022 Filed Mar 14, 2022 16:50 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	165,000	$0.00 Strike: $31.54	$0.00	Disclosure SEC source: 0001209191-22-018495 · doc4.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 28, 2022 Filed Jan 28, 2022 18:32 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	65,000	$0.00 Strike: $12.15	$0.00	Disclosure SEC source: 0001209191-22-005481 · doc4.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 65,000 shares. Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:20 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	4,796	$0.00	$0.00	Disclosure SEC source: 0001567619-21-012328 · doc1.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,701 F1 · shares: The restricted stock award vests as to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date. Read SEC document
May 19, 2021 Filed May 20, 2021 18:59 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	5,000	$17.83	$89,150.00	Disclosure SEC source: 0001209191-21-034601 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $17.78 to $17.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document
March 15, 2021 Filed Mar 17, 2021 21:13 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	92,000	$0.00 Strike: $16.73	$0.00	Disclosure SEC source: 0001209191-21-021617 · doc4.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:09 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	17,905	$0.00	$0.00	Disclosure SEC source: 0001567619-20-012365 · doc1.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,905 F1 · shares: Restricted stock. The restricted stock vests as to 1/3 of the shares on June 16, 2021, another 1/3 of the shares on June 16, 2022 and the final 1/3 of the shares on June 16, 2023. Read SEC document
June 01, 2020 Filed Jun 2, 2020 16:26 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (right to buy) · Derivative	520,000	$0.00 Strike: $14.03	$0.00	Disclosure SEC source: 0001209191-20-033528 · doc4.xml · derivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,000 Underlying: Common Stock · 520,000 shares Expires 2030-06-01 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 18, 2020 Filed May 20, 2020 21:14 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $10.46	$0.00	Disclosure SEC source: 0001209191-20-030948 · doc4.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document
May 18, 2020 Filed May 20, 2020 21:14 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-20-030948 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
May 18, 2020 Filed Jun 3, 2020 20:27 UTC Amendment	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $10.46	$0.00	Disclosure SEC source: 0001209191-20-034015 · doc4a.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document
May 18, 2020 Filed Jun 3, 2020 20:27 UTC Amendment	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034015 · doc4a.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. Read SEC document
March 19, 2020 Filed Mar 20, 2020 21:00 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	Exercise / conversionStock Option (Right-to-Buy) · Derivative	35,000	$0.00 Strike: $5.42	$0.00	Disclosure SEC source: 0001209191-20-020483 · doc4.xml · derivative · entry 3 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2020-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant. Read SEC document
March 19, 2020 Filed Mar 20, 2020 21:00 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	35,000	$6.00	$210,000.00	Disclosure SEC source: 0001209191-20-020483 · doc4.xml · nonDerivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.02 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 19, 2020 Filed Mar 20, 2020 21:00 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	Exercise / conversionCommon Stock	35,000	$5.42	$189,700.00	Disclosure SEC source: 0001209191-20-020483 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. Read SEC document
March 16, 2020 Filed Mar 19, 2020 01:09 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	Exercise / conversionStock Option (Right-to-Buy) · Derivative	15,000	$0.00 Strike: $5.42	$0.00	Disclosure SEC source: 0001209191-20-020143 · doc4.xml · derivative · entry 3 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2020-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant. Read SEC document
March 16, 2020 Filed Mar 19, 2020 01:09 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	15,000	$6.02	$90,261.00	Disclosure SEC source: 0001209191-20-020143 · doc4.xml · nonDerivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019. F3 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.20 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 16, 2020 Filed Mar 19, 2020 01:09 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	Exercise / conversionCommon Stock	15,000	$5.42	$81,300.00	Disclosure SEC source: 0001209191-20-020143 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. Read SEC document
June 10, 2019 Filed Jun 12, 2019 21:06 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0001209191-19-036440 · doc4.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document
June 10, 2019 Filed Jun 12, 2019 21:06 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-19-036440 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
June 11, 2018 Filed Jun 13, 2018 00:24 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $15.65	$0.00	Disclosure SEC source: 0001209191-18-037345 · doc4.xml · derivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-10 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document
June 11, 2018 Filed Jun 13, 2018 00:24 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-18-037345 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
June 11, 2018 Filed Jun 13, 2018 20:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionStock Option (right to buy) · Derivative	29,457	$0.00 Strike: $3.02	$0.00	Disclosure SEC source: 0000899243-18-016350 · doc4.xml · derivative · entry 8 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,942 Underlying: Common Stock · 29,457 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
June 11, 2018 Filed Jun 13, 2018 20:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	SaleCommon Stock, $0.0001 par value	29,457	$30.83	$908,300.70	Disclosure SEC source: 0000899243-18-016350 · doc4.xml · nonDerivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,308 F1 · kind: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $30.51 to $31.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 11, 2018 Filed Jun 13, 2018 20:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionCommon Stock, $0.0001 par value	29,457	$3.02	$89,022.00	Disclosure SEC source: 0000899243-18-016350 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 08, 2018 Filed Jun 8, 2018 21:50 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionStock Option (right to buy) · Derivative	42,106	$0.00 Strike: $3.02	$0.00	Disclosure SEC source: 0000899243-18-015796 · doc4.xml · derivative · entry 15 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,399 Underlying: Common Stock · 42,106 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
June 08, 2018 Filed Jun 8, 2018 21:50 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	SaleCommon Stock, $0.0001 par value	42,106	$30.70	$1,292,511.04	Disclosure SEC source: 0000899243-18-015796 · doc4.xml · nonDerivative · entry 7 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,308 F1 · kind: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $30.22 to $31.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 08, 2018 Filed Jun 8, 2018 21:50 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionCommon Stock, $0.0001 par value	42,106	$3.02	$127,248.54	Disclosure SEC source: 0000899243-18-015796 · doc4.xml · nonDerivative · entry 6 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 07, 2018 Filed Jun 8, 2018 21:50 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionStock Option (right to buy) · Derivative	32,598	$0.00 Strike: $3.02	$0.00	Disclosure SEC source: 0000899243-18-015796 · doc4.xml · derivative · entry 14 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,505 Underlying: Common Stock · 32,598 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
June 07, 2018 Filed Jun 8, 2018 21:50 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	SaleCommon Stock, $0.0001 par value	500	$31.58	$15,790.00	Disclosure SEC source: 0000899243-18-015796 · doc4.xml · nonDerivative · entry 5 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,308 F1 · kind: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Read SEC document
June 07, 2018 Filed Jun 8, 2018 21:50 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	SaleCommon Stock, $0.0001 par value	32,098	$30.95	$993,320.76	Disclosure SEC source: 0000899243-18-015796 · doc4.xml · nonDerivative · entry 4 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,808 F1 · kind: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $30.45 to $31.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.